(QUIK) CTO to Present at Telit DevCon IoT Innovation Conference

(ADAP) Announces New Additions to Manufacturing Senior Management

PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2016  — Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for clinical and commercial scale up with the additions of William Buecheler as Vice President, Manufacturing Operations, and Phil Bassett as Head of Process Development.

Mr. Buecheler is responsible for Adaptimmune’s global manufacturing operations, including contract and in-house manufacturing activities, and is leading the implementation of scale up plans designed to achieve commercial manufacturing capability. Mr. Bassett is responsible for process development activities including leading Adaptimmune’s T-cell and lentivirus process development.

“Adaptimmune is in the midst of scaling up its manufacturing expertise, which significantly enhances our ability to run multiple clinical studies of our TCR therapies and, eventually, commercialize our products,” said James Noble, Chief Executive Officer. “As such, manufacturing excellence is key to our long term success. Hiring the best in the field of manufacturing is critical to us, and Bill and Phil are already making significant contributions.”

Bill Buecheler brings to Adaptimmune over 25 years of industry experience in manufacturing operations, facility planning and expansion, leadership of FDA pre-approval inspection and document preparation, and manufacturing process improvements. He joins Adaptimmune from Novartis Pharmaceuticals, where he acted as the Director and Process Unit Head, with responsibility for overall manufacturing operations of the Cell and Gene Therapy Process Unit. As a member of the senior leadership team, his responsibilities included manufacturing efforts to support the scale up operations for Novartis’ CTL019 chimeric antigen receptor product for treatment of ALL and CLL patients. Prior to joining Novartis, he worked and consulted for numerous pharmaceutical and biotech companies in areas including facility build out and expansion, change control, process improvement, cycle time reduction and critical path project management. Mr. Buecheler earned his Master of Business Administration degree from Syracuse University.

Phil Bassett brings with him over 15 years of process manufacturing experience in CMO, small biotech and large biopharma environments. Most recently, Mr. Bassett served as Head of Manufacturing Development for the Cell Therapy Catapult, a UK-based Center of Excellence in cell therapy, where he was responsible for technology transfer and providing late stage commercial manufacturing, scale-up and process industrialization expertise. Prior to the Cell Therapy Catapult, he served at UCB Celltech as the Associate Director and Head of Fermentation Process Sciences, managing the upstream development team working on clinical and commercial processes, and leading process development, scale up and technology transfer efforts. He also spent several years in roles of increasing responsibility with Cobra Biomanufacturing plc, a UK-based international contract development and manufacturing organization providing biologics for pre-clinical and clinical supply.

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission on October 13, 2015. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T:  (215) 825-9306  
E: will.roberts@adaptimmune.com

Margaret Henry 
Head of PR 
T: +44 (0)1235 430036 
Mob: +44 (0)7710 304249 
E: margaret.henry@adaptimmune.com

(CGIX) Launches Comprehensive Immuno-Oncology Testing Portfolio

• Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients
• Cancer Genetics, Inc. will offer immuno-oncology marker testing and technologies for both solid tumors and blood based cancers

RUTHERFORD, N.J. and LOS ANGELES, Jan. 21, 2016  — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics announced today that it has developed and launched a comprehensive portfolio of tests and technologies to help measure and monitor immuno-oncology markers and select patients for targeted therapies. This portfolio will be available for clinical trials, patient care, and translational research utilizing multiple technological platforms and will be available at CGI’s New Jersey and Los Angeles facilities. In addition, the newly acquired Center of Excellence For Solid Tumor Testing based in Los Angeles, formerly Response Genetics, will also offer the FDA-approved PDL-1 antibody for selection of patients that are most likely to benefit from key immuno-oncology drugs.

Immuno-oncology is a highly promising area of medicine and has already seen several blockbuster therapies enter the market in disease areas such as non-small cell lung cancer and melanoma. Several of these drugs require identification of patients that have a high likelihood of response. As a result, healthcare professionals require identification and potentially companion diagnostics to facilitate patient care.  Clinical trials, targeted therapies that are under development, and many existing approved oncology drugs are undergoing clinical research to identify patient groups that can benefit from stimulating an effective immune response against cancer. The goal is to achieve a more durable or more effective response to the therapy.

Immuno-oncology drugs by themselves have been shown to be highly effective in 20 to 30 percent of patients, and combination therapies are bringing the promise of more significant patient benefits.  In order to develop more effective treatments with fewer side effects, immune-oncology biomarkers and tests helping to assess the effects of therapies will play a key role.

Wall Street analysts are projecting over $35 billion in annual worldwide sales for immuno-oncology drugs by 2024, which would account for half of all spending on cancer drugs, according to market research firm IMS Health. According to pharmaceutical analysts, major pharmaceutical multinational companies are all expected to spend nearly $1 billion a year on immuno-oncology research, early access, and development programs and clinical trials. CGI offers the entire portfolio of immuno-oncology testing and technologies to help pharmaceutical and biotech companies accelerate their clinical trials by integrating immune response data with the genomic and biomarker data that CGI currently provides. This integrated offering will be critical in expanding the CGI value proposition to biotech and pharma companies and increasing the total addressable market for CGI.

“In an era of precision and increasingly personalized therapy, the healthcare industry demands cost-effective options that can robustly identify biomarkers to help select cancer patients most likely to benefit from the emerging class of immuno-oncology drugs,” said Panna Sharma, President and CEO. “CGI has prepared an extensive portfolio of technologies ranging from Immunohistochemistry (IHC) and immuno-phenotyping by flow cytometry to RNA-sequencing. These technologies address the tremendous demand we are experiencing by providing both genomic and immune-marker information to clinical trials and patient care.”

The CGI portfolio of immuno-oncology tests includes immunohistochemistry (IHC)-based tests that can detect novel biomarkers like PD-1 and PD-L1 and flow cytometry-based tests and panels that can assess immune response against cancers by evaluating subsets of immunomodulatory and effector cells. CGI also offers a next generation sequencing (NGS)-based targeted RNA sequencing test that can measure expression levels of drug targets, tumor infiltrate composition, and total immune cell composition. Many of these assays are also available for clinical use and are CLIA- and New York State-approved.

Several drugs targeting PD-1/PD-L1 interactions are currently either FDA approved or in clinical trials. Assessment of PD-L1 expression on tumor cells and in tumor microenvironments is currently used as a biomarker for immunotherapies in patients who fail first-line treatment for non-small cell lung cancer (NSCLC), melanoma, colon cancer, bladder cancer, and hematologic malignancies, among others.

CGI now offers commercial assays for anti-PD-L1 staining and assessment using IHC on formalin-fixed paraffin-embedded (FFPE) tissue for multiple tumor indications, including non-small cell lung cancer (NSCLC), colon adenocarcinoma, melanoma, and several subtypes of non-Hodgkin lymphoma. The in-house expertise of surgical and hemato-pathologists allows reliable evaluation of these markers using complex scoring schemes. Additionally, CGI has capabilities and reporting to integrate genomic and other biomarker data with the immune-marker status to provide a systems approach to measuring and monitoring patients.

CGI will continue expanding the overall capabilities in immuno-oncology and immunotherapy and integrate these capabilities with the genomic and biomarker-based testing being provided in both its New Jersey and Los Angeles centers of excellence.

About Cancer Genetics
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:

Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Media Contact:
Cancer Genetics, Inc.

Marie-Agnes Patrone-Michellod,PhD.

Tel: 201.528.9200

Email: marie.michellod@cgix.com

(HDP) Named a Leader in Big Data Hadoop by Forrester

SANTA CLARA, Calif., Jan. 22, 2016  — Hortonworks, Inc. (NASDAQ: HDP) today announced that it was among the select companies that Forrester Research, Inc. invited to participate in its January 2016 report entitled The Forrester Wave™: Big Data Hadoop Distributions, Q1 2016. In this evaluation, Hortonworks was cited as a Leader and had the highest score in the strategy criterion. According to the Forrester Report, “Enterprise Hadoop is a market that is not even 10 years old, but Forrester estimates that 100% of all large enterprises will adopt it (Hadoop and related technologies such as Spark) for big data analytics within the next two years.”

The Forrester Report noted, “Hortonworks doubles-down on inclusive, broad community innovation. Hortonworks is a rock when it comes to its promise to offer a 100% open source distribution. All of the technology built into HDP is an Apache open source project. Hortonworks will acquire companies to fill enterprise gaps and immediately contributes the code to an Apache project for the good of the community. For example, Hortonworks acquired XA Secure, a company with a commercially licensed security solution, and contributed the code to Apache as Apache Ranger. Hortonworks is also an important member of the Open Data Platform initiative (ODPi) formed earlier this year with IBM, Pivotal Software, and 12 other technology vendors, because the group has adopted Hortonworks-initiated projects such as Apache Ambari. Customers value Hortonworks’ approach to open source innovation.”

Hortonworks Data Platform (HDP™) is the only completely open source Apache™ Hadoop® data platform, architected for the enterprise. With YARN as its architectural center it provides a data platform for multi-workload data processing across an array of processing methods – from batch through interactive to real-time, supported by key capabilities required of an enterprise data platform — spanning Governance, Security and Operations.

“The Big Data and Hadoop markets are changing rapidly thanks to the tremendous amount of work taking place within the Apache community,” said Scott Gnau, chief technology officer, Hortonworks. “We are excited about the opportunity to accelerate the adoption of Open Data Platforms for the enterprise and to continue defining the market for customers.”

About Hortonworks

Hortonworks is the leader in accelerating business transformations with Open Enterprise Hadoop by developing, distributing and supporting an enterprise-scale data platform built entirely on open source technology including Apache™ Hadoop®. Our team comprises the largest contingent of builders and architects within the Hadoop ecosystem who represent and lead the broader enterprise requirements within these communities.

The Hortonworks Data Platform provides an open platform that deeply integrates with existing IT investments and upon which enterprises can build and deploy Hadoop-based applications. Hortonworks has deep relationships with the key strategic data center partners that enable our customers to unlock the broadest opportunities from Hadoop.

For more information, visit www.hortonworks.com. Join us at the Apache Hadoop 10 year anniversary party, held at Hadoop Summit Europe and North America in 2016.

Hortonworks, HDP and HDF are registered trademarks or trademarks of Hortonworks, Inc. and its subsidiaries in the United States and other jurisdictions.

Media contact:
Erin Smith
510.928.4454
comms@hortonworks.com

(HNSN) Announces Exploration of Strategic Alternatives

(GLNG) and Schlumberger sign Memorandum of Understanding

Golar LNG today announced that it has signed a Memorandum of Understanding with Schlumberger to co-operate on the global development of greenfield, brownfield and stranded gas reserves.

Under the Memorandum, Golar and Schlumberger have agreed to jointly market gas monetization solutions to owners, investors and governments. Golar will contribute the Floating LNG assets and technology while Schlumberger, via its special project management division, will provide upstream development knowledge, resources and capital.  The intention of this integrated offer is to gain access to a wide range of uneconomic gas reserves by delivering low-cost LNG production solutions.

This is a ground breaking agreement that will provide resource holders with a completely integrated package both reducing risk and securing financing for gas projects. The main aim of the venture is to accelerated the time it takes to bring proven gas reserves into production.

Both parties have initiated their activities and have already made solid progress expecting to announce the first project within the next two months.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements concerning future events and Golar’s operations, performance and financial condition. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “believe”, “anticipate”, “expect”, “estimate”, “project”, “will be”, “will continue”, “will likely result”, “plan”, “intend” or words or phrases of similar meanings. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Golar’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements.

Golar LNG Limited
Hamilton, Bermuda
22 January, 2016

(MMLP) Partners Announces Quarterly Cash Distribution, Q4 Results

KILGORE, Texas, Jan. 21, 2016  — Martin Midstream Partners L.P. (NASDAQ:MMLP) announced today it has declared a quarterly cash distribution of $0.8125 per unit, or $3.25 per unit on an annualized basis, for the quarter ended December 31, 2015.  The quarterly distribution is unchanged from the distribution paid following the previous quarter.  The distribution is payable on February 12, 2016 to common unitholders of record as of the close of business on February 5, 2016.  The ex-dividend date for the cash distribution is February 3, 2016.

Martin Midstream Partners plans to publicly release its financial results for the fourth quarter ended December 31, 2015 after the market closes on Wednesday, February 24, 2016.  An investors conference call to review the fourth quarter results will be held on Thursday, February 25, 2016 at 8:00 a.m. Central Time. The conference call can be accessed by calling (877) 878-2695.  An audio replay of the conference call will be available by calling (855) 859-2056 from 11:00 a.m. Central Time on February 25, 2016 through 10:59 p.m. Central Time on March 8, 2016.  The access code for the conference call and the audio replay is Conference ID No. 34231812. The audio replay of the conference call will also be archived on Martin Midstream Partners’ website at www.martinmidstream.com.

During the conference call, management will discuss certain non-generally accepted accounting principle financial measures for which reconciliations to the most directly comparable GAAP financial measures will be provided in Martin Midstream Partners’ announcement concerning its financial results for the quarter ended December 31, 2015 which will be available on the investor relations page of Martin Midstream Partners’ website.

Qualified Notice to Nominees

This release serves as qualified notice to nominees as provided for under Treasury Regulation Section 1.1446-4(b)(4) and (d). Please note that 100 percent of the Partnership’s distributions to foreign investors are attributable to income that is effectively connected with a United States trade or business. Accordingly, all of the Partnership’s distributions to foreign investors are subject to federal income tax withholding at the highest effective tax rate for individuals or corporations, as applicable. Nominees, and not the Partnership, are treated as withholding agents responsible for withholding on the distributions received by them on behalf of foreign investors.

About Martin Midstream Partners

Martin Midstream Partners L.P. is a publicly traded limited partnership with a diverse set of operations focused primarily in the United States Gulf Coast region.  The Partnership’s primary business lines include: (1) terminalling, storage and packaging services for petroleum products and by-products; (2) natural gas liquids transportation and distribution services and natural gas storage; (3) sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and (4) marine transportation services for petroleum products and by-products.

Forward-Looking Statements

Statements about Martin Midstream Partners’ outlook and all other statements in this release other than historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements and all references to financial estimates rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside its control, which could cause actual results to differ materially from such statements. While Martin Midstream Partners believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in anticipating or predicting certain important factors. A discussion of these factors, including risks and uncertainties, is set forth in Martin Midstream Partners’ annual and quarterly reports filed from time to time with the Securities and Exchange Commission. Martin Midstream Partners disclaims any intention or obligation to revise any forward-looking statements, including financial estimates, whether as a result of new information, future events, or otherwise.

Additional information concerning Martin Midstream is available on its website at www.martinmidstream.com, or

Joe McCreery – Head of Investor Relations
(903) 988-6425

(AGEN) Announces Clearance of IND Apps for anti-CTLA-4 and anti-GITR Antibodies

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, announced today that the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application for AGEN1884, an immune checkpoint modulator (CPM) antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4). Clearance was also received for a second CPM antibody partnered with Incyte (NASDAQ: INCY) for INCAGN1876, which targets glucocorticoid-induced TNFR-related protein (GITR). Clinical trials for both candidates are expected to begin in the first half of 2016.

“We are pleased with the prospects of both CTLA-4 and GITR moving rapidly into and through the clinic, and in our efforts to bring profoundly effective medicines to cancer patients,” said Garo Armen, PhD, Chairman and CEO of Agenus. “We are also diligently advancing several other product candidates into the clinic and are aiming to begin a number of clinical trials in 2016.”

These two compounds were developed utilizing Agenus’ state-of-the-art monoclonal antibody platform capabilities and leverage the company’s world-class expertise in immuno-oncology and related drug discovery and development. The antibodies were discovered during an earlier collaboration with Ludwig Cancer Research. Recepta, a Brazilian biotech company, was also involved in the collaboration that led to the discovery of AGEN1884, which is partnered with Recepta for certain South American rights. INCAGN1876 is now being co-developed with Incyte.

“CTLA-4 is emerging as an important foundational target for immuno-oncology combination regimens, showing terrific promise when used with other CPMs and cancer vaccines. Our CTLA-4 antagonist antibody, AGEN1884, is a natural potential fit with our expanding vaccine portfolio. This includes Prophage™, slated to enter a randomized placebo-controlled study in newly diagnosed GBM in the second half of 2016, and AutoSynVax™, which we also plan to take into the clinic in the second half of 2016,” said Robert B. Stein, MD, PhD, Agenus’ President, Research & Development. “I would like to acknowledge the research and development teams at Agenus, and Incyte for GITR, for their tireless efforts to achieve our goal of filing these INDs by the end of 2015.”

About Checkpoint Modulators

Promising clinical data from studies employing monoclonal antibodies that bind to checkpoint molecules, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have generated considerable excitement in the field of cancer immunotherapy. These molecules serve as checks employed by the body to prevent a runaway immune response, which can be debilitating, and even deadly. Unfortunately, these necessary mechanisms of control can hinder the anti-cancer immune response. They can be harnessed by cancer cells as a defense against immune attack. Agenus is developing a broad pipeline of antibodies that bind to key checkpoint proteins and activate or block their activities for use in cancer therapy.

About Agenus

Agenus is an immunotherapy company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach to target identification and validation, and for the discovery, development and manufacturing of monoclonal antibodies that modulate targets of interest. The company’s broad portfolio of novel checkpoint modulator and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. Agenus’ heat shock protein-based vaccine, Prophage™, has successfully completed Phase 2 studies in newly-diagnosed glioblastoma. The company is collaborating with Merck and Incyte to discover and develop multiple checkpoint modulators. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding planned clinical trial activities of Agenus and its partners, as well as the efficacy of certain product candidates. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of Agenus’ Form 10-Q filed with the Securities and Exchange Commission on November 4, 2015. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Agenus:
Agenus Inc.
Michelle Linn, 774-696-3803
michelle.linn@agenusbio.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com

(CPST) Receives Additional Follow-on Order for Australian Coal Seam Gas Company

CHATSWORTH, Calif., Jan. 21, 2016  — Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today that it received an additional follow-on order for a large Australian coal seam gas company.

The initial order in July 2008 was for the supply of 112 C30 microturbines, which was later increased to 154 C30s in 2009. The first follow-on contract was for 44 C30 microturbines in September 2012, and in January 2013 they ordered 36 additional units, followed by another 14 units in December 2013. This latest order is for another 8 units, bringing the total number of microturbines sold to date to 256. These orders are part of a periodical supply contract for the life of the coal seam development project.

“The coal seam gas market continues to develop as coal seam operators convert this gas into clean on-site power generation,” said Darren Jamison, Capstone’s President and Chief Executive Officer. “It’s rewarding to see satisfied repeat customers continue to come back and add to their already large fleets of operating microturbines. In addition, Australia has been a key geographical focus for Capstone, similar to Latin America, Africa and the Middle East,” added Mr. Jamison.

Optimal Group, Capstone’s Australian distributor, secured the latest follow-on order, which is currently scheduled to be commissioned in mid-2016. In Australia, coal seam gas is plentiful. Coal seam gas has been known about ever since the coal mining industry began in Australia in the early 1900s. With advances in technology, it has developed into a key transition fuel, helping to lower Australia’s carbon emissions as the country moves to a lower carbon future.

“Optimal Group’s business in Australia continues to expand in oil and gas, coal seam gas and the combined heat and power markets. In fact, they are currently our second largest distributor in terms of revenue generation over the trailing four quarters,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing. “I am confident that Australia will deliver substantial growth year-over-year and help offset slowdowns in other geographies,” added Mr. Crouse.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST) is the world’s leading producer of low-emission microturbine systems and was the first to market commercially viable microturbine energy products. Capstone Turbine has shipped over 8,600 Capstone Microturbine systems to customers worldwide. These award-winning systems have logged millions of documented runtime operating hours. Capstone Turbine is a member of the U.S. Environmental Protection Agency’s Combined Heat and Power Partnership, which is committed to improving the efficiency of the nation’s energy infrastructure and reducing emissions of pollutants and greenhouse gases. A UL-Certified ISO 9001:2008 and ISO 14001:2004 certified company, Capstone is headquartered in the Los Angeles area with sales and/or service centers in the New York Metro Area, United Kingdom, Mexico City, Shanghai and Singapore.

The Capstone Turbine Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6212

This press release contains “forward-looking statements,” as that term is used in the federal securities laws, about the advantages of our products and the growth of the coal seam gas market. Forward-looking statements may be identified by words such as “expects,” “objective,” “intend,” “targeted,” “plan” and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone’s filings with the Securities and Exchange Commission that may cause Capstone’s actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“Capstone” and “Capstone MicroTurbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: 
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

INVESTORS:
Dian Griesel Int’l
Cheryl Schneider/Tom Caden
212-825-3210

(UPIP) Wins German Cellular Essential Patent Infringement Case Against Samsung

Unwired Planet, Inc. (NASDAQ:UPIP) today announced that the Düsseldorf District Court in Germany issued its judgments that cell phone and infrastructure manufacturers Samsung, LG Electronics and Huawei each infringe multiple Unwired Planet patents. The judgments come after an initial trial held in June 2015 against Huawei, and a multi-day trial held in late November and December 2015 against the other defendants.

Confirmation of Infringement

The Düsseldorf District Court court held that the defendants’ LTE and GSM compliant handsets infringe three Unwired Planet patents: EP (DE) 2,119,287 and EP (DE) 2,485,514, and EP (DE) 1 230 818. With respect to infrastructure equipment, the court found that Samsung and Huawei’s infrastructure equipment infringes patent EP (DE) 2,119,287 but not patent EP (DE) 2,485,514.

The defendants filed actions with the German Federal Patent Court alleging that the patents are invalid; however, the Düsseldorf court did not grant a stay of the proceedings. The court ruled that it did not find a sufficient likelihood that these actions, called “nullity actions” in Germany, would be successful. In the German case, claimant Unwired Planet International Ltd. was represented by Ben Grzimek of the EIP Law Firm and Hosea Haag of the Ampersand firm.

“This is a great result and certainly increases our chances of being fairly and properly compensated,” said Unwired Planet CEO Boris Teksler. “This judgment marks one of the few decisions in Europe after the landmark Huawei v. ZTE decision last July governing the conduct of FRAND licensing. This decision solidifies wins in two jurisdictions and increases the number of cellular standard essential patents to four that have been positively adjudicated by the courts.”

On July 16, 2015, the Court of Justice of the European Union (CJEU), the highest appellate court in the European Union, provided needed guidance regarding the obligations of both patent holders who want to assert their standard essential patents and the alleged infringers who wants to rely on the FRAND license defense (Huawei v ZTE, 16 July 2015, Case C-170/13).

“The CJEU set out the general principles for both licensors and licensees. To date we’ve only sought monetary damages for the defendants’ infringement,” said Unwired Planet general counsel Noah D. Mesel. “The CJEU’s licensing principles specify that patent holders may seek injunctive relief in certain circumstances if the infringer fails to negotiate in good faith with the patent holder on the terms of a license.”

UK Litigation Update

As is widely known, the UK courts employ a “loser-pays” fee-shifting system. On December 16, 2015, the Court ordered Samsung and Huawei to make an initial partial payment of £1,270,800 (approximately $1.9 million) on account of Unwired Planet’s legal fees for the first UK trial. Those payments now have been made. If the parties do not agree on a total fee amount due to Unwired Planet, a further hearing will be calendared.

On a related note Samsung and Huawei have filed an appeal of the UK High Court’s decision of the findings of validity and infringement of the EP (UK) 2 229 744 patent. The court has not set a briefing or hearing schedule on that appeal.

Unwired Planet concluded a second trial in the UK in mid-December and expects to receive a ruling from the UK High Court before the end of January 2016 on EP (UK) 2,119,287 and EP (UK) 2,485,514.

About Unwired Planet, Inc.

Unwired Planet, Inc. (NASDAQ:UPIP) is the inventor of the Mobile Internet and a premier intellectual property company focused exclusively on the mobile industry. The company’s patent portfolio of approximately 2,500 issued and pending US and foreign patents, includes technologies that allow mobile devices to connect to the Internet and enable mobile communications. The portfolio spans 2G, 3G, and 4G technologies, as well as cloud-based mobile applications and services. Unwired Planet’s portfolio includes patents related to key mobile technologies, including baseband mobile communications, mobile browsers, mobile advertising, push notification technology, maps and location based services, mobile application stores, social networking, mobile gaming, and mobile search. Unwired Planet is headquartered in Los Altos, California. References in this release to Unwired Planet may be to Unwired Planet, Inc. or its subsidiaries.

The Blueshirt Group
Lauren Sloane, 415-217-2632
Lauren@blueshirtgroup.com

(TROV) Agreement with America’s Choice Provider Network

Agreement provides in-network coverage for 22 million individuals

SAN DIEGO, Jan. 21, 2016  — Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America’s Choice Provider Network (ACPN®) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer Monitoring℠ (PCM) tests and services. Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.

“We are very much looking forward to having a provider as progressive and innovative as Trovagene in our national provider network,” said Seth Breeden, chief operating officer of ACPN. “It is with great excitement that we can now offer our members access to Trovagene’s Precision Cancer Monitoring services.”

“We are pleased that ACPN has agreed to provide coverage for Trovagene’s PCM full offering of ctDNA products,” said Matt Posard, chief commercial officer of Trovagene. “Our commercial plan is on track to provide national sales coverage, and ACPN is the first of several additional contracts expected this year. In support of our commercialization program, we are creating a strong foundation of data from our clinical studies and manuscript publications demonstrating the medically actionable use of Trovagene’s liquid biopsy platform in the treatment of cancer.”

About America’s Choice Provider Network

Founded in 2012, ACPN is an independent, multispecialty national provider network. Through its proprietary network and technology, ACPN offers access to providers, payers and patients in all 50 States, Canada, the Dominican Republic, Guam, Mexico, and Puerto Rico. ACPN’s products include Individual and Group Health, Workers Compensation, Auto Liability, and Medicare Advantage. Its client base consists of Insurance Carriers, Third Party Administrators, Health and Welfare Funds, Self-Administered Employer Groups, Student Plans, Travel Plans, etc. ACPN’s mission is to achieve consistency in healthcare transactions, simplify claims adjudication processes, create reasonable reimbursement arrangements, and establish reliable healthcare access for all parties—providers, payers and patients.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition;  our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

(SYNA) Unveils Tiny Footprint, Low Power Touch Controller for Small Screens

New S1423 Ideal for Smartwatches, Emerging Wearables, Diverse Touchscreens

SAN JOSE, Calif., Jan. 20, 2016  — Synaptics Incorporated (NASDAQ: SYNA), the leading developer of human interface solutions, today announced sampling of S1423, its newest ClearPad^® touch controller solution for wearables and small screen applications including smartwatches, fitness trackers, and touch enabled appliances such as printers. Supporting round and rectangular shapes, as well as thick and curved lenses, the S1423 offers excellent performance with moisture on screen, while wearing gloves, and supports swipes and gestures including the Android Wear ‘home’ gesture.

Fully optimized and redesigned from the ground up for wearables, the new Synaptics S1423 supports a low-cost single layer sensor design and enables narrow borders. Synaptics’ unique Advanced Matrix Pad (AMP) technology enables industry leading touch accuracy and sensitivity. With less than 6mW active power, the S1423 is highly optimized for small screen wearables where low power is of critical importance.

Synaptics’ first generation wearables solution, the S1222, is in full production and found in many of today’s shipping smartwatches. Beyond wrist wearables, early smart glasses innovators chose Synaptics’ touch solution, while OEMs developing new smart eyewear products are choosing the S1423 due to its improved performance and lower power.

“The user experience is critical with very small screen applications, and we purpose-built these solutions specifically for the wearables market,” said Tim Vehling, vice president, Smart Displays Division, Synaptics. “Our human interface expertise provides unique and proven results. The S1423, with very low power, advanced touch capabilities, and small form factor address this market perfectly.”

About Synaptics:
Synaptics is the pioneer and leader of the human interface revolution, bringing innovative and intuitive user experiences to intelligent devices. Synaptics’ broad portfolio of touch, display, and biometrics products is built on the company’s rich R&D, extensive IP and dependable supply chain capabilities. With solutions designed for mobile, PC and automotive industries, Synaptics combines ease of use, functionality and aesthetics to enable products that help make our digital lives more productive, secure and enjoyable. (NASDAQ: SYNA) www.synaptics.com.

Follow Synaptics on Twitter and LinkedIn, or visit synaptics.com.

Synaptics, ClearPad, and the Synaptics logo are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.

For further information, please contact:
David Hurd, Synaptics, Incorporated
+1-408-904-2766
david.hurd@synaptics.com

Public Relations:
Text 100 Global Communications
Marcelo Vilela
+1-415-593-8419
synaptics@text100.com

(APHB) Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.

“This is a key step in the development of a novel therapy to treat an extremely under-served population that exacts a significant financial toll on the healthcare system and the economy,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “Each year, nearly 13 percent of the U.S. population suffers from CRS, resulting in a productivity loss of over $10,000 per person, for a total annual loss in the United States of more than $350 billion. Our goal is to develop a better treatment for this common condition in order to alleviate tremendous suffering, especially in the estimated 2.6 million CRS patients who fail to respond to standard antibiotic treatment and resort to endoscopic surgery, yet continue to be plagued by the disease.”

AmpliPhi’s Phase 1 clinical trial is enrolling patients with CRS – defined as serious, often debilitating infection and inflammation of the nose and sinuses lasting 12 weeks or more – who have not responded to surgery and are infected with S. aureus. AmpliPhi expects to complete enrollment of the trial by the end of the first half of 2016.

“We are confident in our bacteriophage-based approach to treating infection in CRS patients, and we are grateful to our partners at University of Adelaide’s Queen Elizabeth Hospital and Flinders University for their dedication and commitment to moving this important research forward,” continued Mr. Salka.

For more information, visit www.ampliphibio.com.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSEMKT:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE:XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to advance bacteriophage-based therapies.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the expected timing to complete enrollment of patients in AmpliPhi’s Phase 1 clinical trial of AB-SA01 for the treatment of S. aureus, the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics, and AmpliPhi’s development of bacteriophage-based therapies. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon AmpliPhi’s current expectations and involve a number of risks and uncertainties, including the risks and uncertainties described in AmpliPhi’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Company and Investor relations:
AmpliPhi Biosciences
Matt Dansey
+1 858-800-4869
md@ampliphibio.com
or
Media relations (USA)
Lazar Partners
Danielle Lewis/Glenn Silver
+ 1 212-867-1762
ampliphi@lazarpartners.com
or
Media Relations (Europe and ROW)
Instinctif Partners
Gemma Howe/Sue Charles
+44 (0)20 7866 7905
ampliphi@instinctif.com

(OPTT) APB350 (A1) PowerBuoy Achieves Significant Performance Milestones

PENNINGTON, N.J., Jan. 20, 2016  — Ocean Power Technologies, Inc. (Nasdaq:OPTT) today announced that its APB350 (A1) PowerBuoy^® has achieved several significant milestones.  Total cumulative deployment time has exceeded 125 days and energy generated has surpassed 1,000 kWh (1MWh).  In addition, a new maximum generation record of 32 kWh of energy for a 24-hour period was achieved.  The APB350 A1, deployed off of the coast of New Jersey, has communicated key performance as well as meteorological data from the buoy’s integrated weather station.

George H. Kirby, President and Chief Executive Officer of OPT, stated, “We continue to be very excited by the A1’s overall performance, specifically its power generation in extreme ocean conditions.  The A1 results are significant as it continues to confirm design robustness and demonstrates measurable progress toward commercial readiness on three key focus areas: the PTO; the survivability of the PowerBuoy system during high sea states; and the linear seal, which prevents water from entering the buoy.”

Dr. Mike M. Mekhiche, OPT’s Vice President of Engineering, stated, “In addition, the A1 has provided critical design, performance, and in-ocean operating data.  The new 24-hour energy record is 3.8 times its nameplate daily rating of 8.4 kWh, which is a 14% improvement over the previously reported record.”

Dr. Mekhiche continued, “The A1 also demonstrated its ability to generate sufficient power at very low sea states, which is further confirmation of the PTO efficiency improvements as compared to the original design.  These improvements expand the buoy’s mission persistence and endurance capabilities in terms of providing required power to its payload over longer “zero wave” periods.  This persistence is critical for a variety of autonomous offshore power markets of interest.”

OPT also announced that it will retrieve the A1 for necessary inspection, repairs and maintenance.  The PowerBuoy has been deployed since October, and it will be redeployed at the earliest available weather window.  Upon redeployment, sea trials of the A1 will continue off the coast of New Jersey to further validate the buoy reliability and survivability with periodic inspections as needed.

Dr. Mekhiche stated, “Further progress was also made on the ALT testing, which continues to validate the PTO design and generate important data on its reliability and life.  The ALT process consists of operating PTOs in tandem with accelerated operating profiles, which subjects the PTOs to various load conditions encountered in extreme sea states.  The objective of the test is to simulate an equivalent three-year ocean deployment during a period of approximately nine months using PTOs that are identical to those of the A1.  The ball screw PTO has traveled the equivalent of approximately 1,200 km so far, corresponding to approximately 1.8 million strokes, without any mission critical issues.  The PTO ALT, which is currently operating 24/7, has already exceeded the deployed A1 PTO in terms of strokes and total distance traveled by the PTO.

Mr. Kirby concluded, “We continue to believe that the combination of sea trials, ALT, and feedback from the Technical Advisory Panel are helping us shorten our product’s validation and market introduction time.  We are receiving significant commercial interest resulting from the positive sea trials and ALT results, which supports our goal of 2016 commercialization.”

About Ocean Power Technologies

Headquartered in Pennington, New Jersey, Ocean Power Technologies (Nasdaq:OPTT) is a pioneer in renewable wave-energy technology that converts ocean wave energy into electricity. OPT’s proprietary PowerBuoy^® technology is based on a modular design and has undergone periodic ocean testing since 1997. OPT specializes in cost-effective and environmentally sound ocean wave based power generation and management technology.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Company Contact:
Mark A. Featherstone, 
Chief Financial Officer of OPT 
Phone:
609-730-0400

Investor Relations Contact:
Andrew Barwicki
Phone:
516-662-9461

(ZFGN) Phase 3 Beloranib Trial in Prader-Willi Achieves Co-Primary Efficacy Endpoints

– bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-related behaviors in PWS patients-

-Statistically significant at both 2.4 mg and 1.8 mg dose levels-

-Company plans to discuss results and path forward for beloranib with the FDA-

-Conference call scheduled for 8:30 AM Eastern Time-

BOSTON, Jan. 20, 2016  — Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today positive efficacy results from the bestPWS ZAF-311 study, a pivotal, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with Prader-Willi syndrome (PWS) during a six-month randomized treatment period. The clinical trial achieved its co-primary efficacy endpoints, as beloranib demonstrated a statistically significant reduction in both body weight and hyperphagia-related behaviors, making it the first investigational drug to demonstrate a positive impact on these two hallmark challenges in PWS.

Treatment with the 2.4 mg and the 1.8 mg doses of beloranib resulted in 9.45 percent (p<0.0001) and 8.20 percent (p<0.0001) reductions in body weight relative to placebo, respectively. Treatment with the 2.4 mg and the 1.8 mg doses of beloranib also resulted in reductions of hyperphagia-related behaviors of 7.0 units (p=0.0001) and 6.3 units (p=0.0003) relative to placebo, respectively, as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT).

“This clear efficacy outcome is a crucial first step in moving discussions forward with the Food and Drug Administration regarding continued development of beloranib,” stated Thomas Hughes, Ph.D., Chief Executive Officer of Zafgen. “While we take the previously reported adverse events very seriously, we now have the robust data to provide greater perspective on the benefit/risk relationship of beloranib in this high-risk patient population. We thank our investigators, and the patients and their families for participating in the bestPWS ZAF-311 clinical trial.”

PWS is the most common genetic cause of life-threatening obesity. Pathologic hunger-related behaviors, known as hyperphagia, dominate the lives of individuals with PWS, and drive patients to engage in problematic behaviors which can lead to excessive overeating, choking, and stomach rupture. Compounding the morbid obesity in PWS is slowed metabolism, psychiatric conditions including aggression, anxiety, and psychosis, higher risk for cardiopulmonary and metabolic co-morbidities; all of which contribute to a higher risk of obesity-related mortality.

“Prader-Willi syndrome significantly impacts the quality of life of affected individuals and their families, as it drives patients to engage in excessive overeating, or hyperphagia, and may also lead to morbid obesity, which can be life-threatening if not controlled,” said Merlin G. Butler, M.D., Ph.D., FFACMG, Professor of Psychiatry, Behavioral Sciences and Pediatrics, Director, Division of Research and Genetics, Department of Psychiatry, Behavioral Sciences and Pediatrics at the Kansas University Medical Center. “There are no treatment options for these life-limiting problems, so I believe the significant improvements seen in both hyperphagia and obesity in patients receiving beloranib during this six-month clinical trial are clinically meaningful and support a strong rationale for continued evaluation of beloranib as a potential treatment for PWS.”

On December 2, 2015, the Food and Drug Administration (FDA) notified Zafgen that the beloranib investigational new drug (IND) application had been placed on complete clinical hold due to an imbalance in severe venous thromboembolic events, including two patient deaths. In order to address the clinical hold, Zafgen plans to present to the FDA the efficacy and safety data from the bestPWS ZAF-311 study, data from the Phase 2b trial of beloranib in severe obesity complicated by type 2 diabetes, ZAF-203, expected later this quarter, and a proposal for a risk mitigation strategy for beloranib in PWS.

“We are actively working to better understand the mechanisms and incidence of underlying thromboembolic disease in PWS, as well as the potential impact of beloranib treatment on thrombosis in order to develop a strategy for risk mitigation in this underserved patient population,” Dr. Hughes said. “We plan to continue our dialog with the FDA given the robust efficacy results seen in the ZAF-311 trial.”

BestPWS ZAF-311 Efficacy and Safety Results

The bestPWS ZAF-311 study randomized 107 patients to receive twice-weekly subcutaneous injections of either 2.4 mg or 1.8 mg of beloranib or placebo. Seventy-four patients completed the full 26 weeks of treatment per the trial protocol, and 27 patients completed at least 75 percent of the randomized treatment period prior to the suspension of dosing in the trial in October 2015. There were six patients who discontinued early. The co-primary efficacy endpoints for this trial were improvement in hyperphagia-related behaviors and reduction in body weight. Patients in the trial were on average 20 years old, had an average BMI of 40 kg/m² and an average hyperphagia total score of 16.9, consistent with moderate to severe hyperphagia, at the beginning of randomized treatment. These baseline characteristics were well-balanced across the treatment arms. In agreement with the FDA, Zafgen has analyzed the data using a mixed model repeated measures (MMRM) approach to account for the missing endpoint data of the patients who did not complete the clinical trial.

Patients in the ZAF-311 trial were markedly obese at baseline. Patients randomized to receive placebo displayed substantial (4.15%) gain in body weight over the course of the six months of randomized treatment. Body weight gain in this patient population was anticipated, and typically occurs throughout life generally due to lack of effective treatments for managing obesity. Patients treated with beloranib, in contrast to placebo, lost weight, with the 2.4 mg dose arm displaying a 5.3 percent reduction from baseline, with a placebo-adjusted weight loss of 9.45 percent.

The HQ-CT is a PWS-specific study instrument that provides an assessment by caregivers of the food-seeking behaviors exhibited by patients. The scale provides a composite value from nine questions, each rated on a scale of zero to four units (total range of score of zero to 36). Patients in the ZAF-311 trial were enrolled only if their baseline HQ-CT total score was greater than 12 units, representing moderate-to-severe hyperphagia related behaviors at baseline. While hyperphagia-related behaviors were stable over six months of treatment in the placebo arm, both the 2.4 mg and 1.8 mg beloranib arms showed highly statistically significant reductions in HQ-CT total score, indicative of reduced hunger-associated behaviors.

The most common adverse events (AEs) were injection site bruising, aggression, and hyperphagia, generally of mild and transient nature. Of these, only injection site bruising was notable as being reported more frequently in patients taking beloranib compared to placebo. There were a total of five serious adverse events (SAEs); aggression (placebo, 2.4 mg beloranib), ankle fracture (placebo), mental status change (1.8 mg beloranib), and pulmonary embolism (1.8 mg beloranib). Four patients withdrew due to adverse events in the 1.8 mg beloranib treatment group (abnormal behavior, anxiety, mental status changes, and pulmonary embolism) and two patients in the 2.4 mg beloranib group (injection site pain and psychotic disorder). Many of these adverse events, specifically psychiatric disorders, are commonly observed as background comorbidities in PWS patients. At the end of the randomized treatment period, there were no clinically significant abnormal patterns regarding laboratory values, vital signs, or electrocardiography (ECG) findings. As previously disclosed, across the completed trials comprising the beloranib clinical program, there has been an association of venous thromboembolic events reported in patients treated with beloranib versus placebo, including one fatal case of pulmonary embolism (1.8 mg beloranib) during the randomized portion of the bestPWS study that was reported in October 2015. No other venous thromboembolic events were reported during the blinded randomized portion of the bestPWS study. As previously reported, a second patient death associated with pulmonary embolism (2.4 mg beloranib) and two cases of deep vein thrombosis (1.8 mg and 2.4 mg beloranib) occurred during the open-label extension portion of the bestPWS study. No other deaths have occurred in the course of the beloranib program.

Zafgen plans to present the full safety and efficacy data set from the bestPWS Phase 3 trial, including impact on body composition, cardiovascular disease risk markers, metabolic endpoints, and quality of life measures at upcoming medical meetings.

Conference Call Information

Zafgen will host an investor conference call today, January 20, 2016 at 8:30 a.m., Eastern Time, to discuss the trial results in more detail. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States. The call will also be webcast live on the Company’s website at http://ir.zafgen.com/events.cfm. You can access the replay for seven days by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States and referencing conference ID number 32720188.

About Beloranib

Beloranib is a novel, first-in-class injectable small molecule therapy that works by inhibiting MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism. Once a person becomes obese, the body undergoes certain metabolic changes and becomes “programmed” to create and store more fat, making it much more difficult to reduce body weight. Beloranib is believed to help reduce hunger and restore balance to fat metabolism, enabling calories to once again be used as a productive energy source. Because beloranib works beyond just regulating hunger through the hypothalamus, it has the potential to be used in a variety of complex metabolic disorders such as Prader-Willi syndrome and hypothalamic injury associated obesity. Zafgen holds exclusive worldwide rights (exclusive of South Korea) for the development and commercialization of beloranib. Zafgen exclusively licensed beloranib from Chong Kun Dang Pharmaceutical Corporation (CKD Pharma) of South Korea.

About Prader-Willi Syndrome (PWS)

Prader-Willi syndrome (PWS), is the most common known genetic cause of life-threatening obesity. A dysfunctional signaling to the hypothalamus results in constant and unrelenting perception of starvation, driving patients with PWS to engage in problematic hunger-related behaviors, known as hyperphagia, and to gain excessive weight. As a result, many of those affected with PWS become morbidly obese and suffer significant mortality. Currently, there is no cure for this disease. Although the cause of PWS is complex, it results from a deletion or loss of function of a cluster of genes on the 15th chromosome. PWS typically causes low muscle mass and function, short stature, incomplete sexual development, and a chronic feeling of hunger that, when coupled with a metabolism that utilizes drastically fewer calories than normal, can lead to excessive eating and life-threatening obesity. PWS occurs in males and females equally and in all races, with the same incidence around the world. Prevalence estimates have ranged from 1:8,000 to 1:50,000.  Patients with PWS have a shortened life expectancy of approximately 32 years, as a result of an estimated three percent annual death rate for the PWS population.  Common causes of mortality in PWS include respiratory disease, cardiac disease, infection, choking, gastric rupture, and pulmonary embolism.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen’s lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.

Safe Harbor Statement

Various statements in this release concerning Zafgen’s future expectations, plans and prospects, including without limitation, Zafgen’s expectations regarding beloranib as a treatment for PWS, obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity, and other forms of severe obesity, including severe obesity in patients with type 2 diabetes, Zafgen’s expectations with respect to the timing and success of its clinical trials of beloranib and its other product candidates, the expected requirements and timing of additional requirements for planned clinical trials, and the need for  additional clinical trials and pre-clinical studies, and Zafgen’s plans regarding commercialization of beloranib may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen’s ability to obtain a release of the full clinical hold that the FDA placed on the investigational new drug application for beloranib, Zafgen’s ability to successfully demonstrate the efficacy and safety of beloranib and its other product candidates, the pre-clinical and clinical results for beloranib and its other product candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect the initiation, timing and progress of preclinical studies and clinical trials, Zafgen’s ability to obtain, maintain and protect its intellectual property, Zafgen’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen’s ability to manage operating expenses, Zafgen’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Zafgen’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Zafgen’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Zafgen’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Zafgen’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media/Investor Relations Contact:

Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792

Argot Partners
Investor Relations
David Pitts or Laura Perry
212-600-1902
david@argotpartners.com
laura@argotpartners.com

Spectrum Science
Media Relations
Susan Francis
609-529-0676
sfrancis@spectrumscience.com

(MOXC) Enters Exclusive Agreement, Development Partnership With Xinhua Media Affiliate

(SKLN) ARIN Partners With Skyline Medical to Promote Imaging and Radiology

MINNEAPOLIS, Jan. 19, 2016  — Skyline Medical Inc. (Nasdaq:SKLN) (Nasdaq:SKLNU) (“Skyline” or the “Company”) announced today that, as part of the continuing expansion of its sales strategy, the Company has entered into a partnership with the Association for Radiologic & Imaging Nursing (“ARIN”) to market Skyline products and services to medical professionals performing paracentesis and thoracentesis procedures.

Josh Kornberg, President and CEO of Skyline Medical, commented, “Our research has shown that most radiology and imaging rooms do not currently use, nor are they aware of automated fluid disposal technology, despite the major potential safety and cost benefits. As it is the nurses and technologists that often perform these procedures and can help influence purchasing decisions, we expect our partnership with ARIN to create new sales opportunities.”

Under the terms of the partnership, Skyline Medical will sponsor ARIN and ARIN will provide Skyline Medical with access to nurses in the imaging and radiology space. In conjunction with their partnership, Skyline Medical will have the opportunity to attend the ARIN Spring Convention in Vancouver on April 3. Skyline’s sales representatives will demonstrate Skyline products to nurses, technologists and other decision makers in the industry.

About ARIN
The Association for Radiologic & Imaging Nursing (ARIN) was founded in 1981 as the professional organization representing nurses who practice in the diagnostic, neuro/cardiovascular, interventional, ultrasonography, computerized tomography, nuclear medicine, magnetic resonance, and radiation oncology areas.

ARIN’s goal is to partner with strategic organizations that can enhance the radiology and imaging profession in addition to providing new benefits to ARIN’s members. New partnership arrangements are vetted thoroughly for any conflicts of interest or standards outside of our core purpose. As ARIN grows, we will continue to provide additional educational opportunities and services for our membership through strategic alliances from within the nursing community.

About Skyline Medical Inc.
Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods — which require hand carrying and emptying filled fluid canisters and glass bottles — present an exposure risk and potential liability. For additional information, please visit: www.skylinemedical.com.

Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.

Contacts:
ARIN Contact 
Bruce Boulter
Executive Director
Association for Radiologic and Imaging Nursing
866-486-2762
bruce.boulter@arinursing.org

Skyline Investor Relations Contact:
Garth Russell 
KCSA Strategic Communications
212-896-1250 
skyline@kcsa.com

(AEZS) Phase 3 Trial of Macrilen Confirmatory Meeting Successful

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (“AGHD”). As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.

Dr. Richard Sachse, the Company’s Chief Scientific Officer stated, “On January 16, we held an Investigators’ Meeting for our multi-center confirmatory Phase 3 clinical trial of Macrilen™. The purpose of the meeting was to review Macrilen™ with the investigators, as well as the clinical trial protocol. The 77 investigators and site personnel who attended the meeting included Jose Manuel Garcia, MD, PhD, Associate Professor of Medicine at University of Washington School of Medicine, Seattle, who is serving as coordinating investigator. Dr. Garcia expressed his commitment to the development of Macrilen™ because of the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”

Patients who are believed to have AGHD are now very often evaluated by means of the insulin tolerance test (“ITT”). The ITT is the historical gold standard for the evaluation of AGHD because of its high sensitivity and specificity. However, the ITT is inconvenient to the patients and physicians and contra-indicated in certain patients, such as patients with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain a result. Some physicians will not induce full hypoglycemia, intentionally compromising accuracy to increase safety and comfort for the patient. Furthermore, administration of the ITT is expensive because the patient must be constantly monitored by a physician for the 2-4 hour duration of the test and the test must be administered in a setting where emergency equipment is available and where the patient may be quickly hospitalized. The ITT is not used for patients with co-morbidities, such as CV, seizure disorder or a history of brain cancer or for patients who are elderly and frail, due to safety concerns.

The Company believes that Macrilen™, if it is approved, is likely to be rapidly adopted by physicians as the preferred means of evaluating AGHD for the following reasons:

• it is safer than the ITT because it does not require the patient to become hypoglycemic;
• Macrilen™ is administered orally, while the ITT requires an intravenous infusion of insulin;
• the evaluation of AGHD using Macrilen™ is much less time consuming and labor intensive than the ITT and, therefore, it is less expensive to conduct; and
• the evaluation can be conducted in the physician’s office rather than in a hospital setting.

About the Study

The confirmatory Phase 3 clinical study of Macrilen™, entitled Confirmatory validation of oral macimorelin as a growth hormone (GH) stimulation test (ST) for the diagnosis of adult growth hormone deficiency (AGHD) in comparison with the insulin tolerance test (ITT), is designed as a two-way crossover study with the insulin tolerance test as the benchmark comparator and will involve some 30 sites in the United States and Europe. The study population will consist of approximately 110 subjects (at least 55 ITT-positive and 55 ITT-negative) with a medical history documenting risk factors for AGHD, and will include a spectrum of subjects from those with a low risk of having AGHD to those with a high risk of having the condition. The primary endpoint is validation of a single oral dose of macimorelin for the diagnosis of AGHD, using the ITT as a comparator. Based on meetings with the US Food and Drug Administration (“FDA”) as well as the European Medicines Agency (“EMA”) and subsequent written scientific advice, the Company believes that the study meets the FDA’s and the EMA’s study-design expectations allowing US and European approval, if successful. As of the date of this release, five patients at three separate centers have been enrolled in the study. For more details on the trial, please consult this link:

https://www.clinicaltrial.gov/ct2/show/NCT02558829?term=macimorelin&rank=1.

Based on the current rate of enrollment, the Company expects the confirmatory Phase 3 clinical study of Macrilen™ to be concluded by the end of 2016. The Company further expects to be able to submit a New Drug Application for Macrilen™ to the FDA by mid-year 2017 and, if the study is successful in meeting its primary endpoint, to obtain approval of the drug by year-end 2017.

About Macrilen^TM (macimorelin)

Macimorelin, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. Macimorelin, under the trade name Macrilen^TM, has been granted orphan drug designation by the FDA for diagnosis of AGHD. The Company owns the worldwide rights to this novel patented compound.

About AGHD

AGHD affects approximately 75,000 adults across the US, Canada and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

Aeterna Zentaris Inc.
Philip A. Theodore
Senior Vice President
843-900-3223
ir@aezsinc.com

(ANY) Multi-Site National Call Center Selects Sphere 3D’s Hybrid Cloud Solutions

Surpass, LLC call centers to virtualize workloads with V3 and Glassware 2.0, increase onsite storage efficiencies with SnapServer, and provide Cloud Storage via SnapCLOUD on Microsoft Azure

San Jose, California–(January 19, 2016) – Sphere 3D Corp. (NASDAQ: ANY), a containerization, virtualization and data management solutions provider, today announced that Surpass, LLC (“Surpass”), a national call center headquartered in Lynchburg, VA will upgrade two of its call centers with Sphere 3D’s hybrid cloud offerings.

“We have worked very hard over the past year to enhance, refine and align our products. Our strategy of vertically integrating our portfolio to deliver turnkey hybrid cloud offerings now allows us to provide highly impactful solutions to our customers” said Peter Bookman, Global Strategist at Sphere 3D. “I am pleased that we were selected by Surpass, and look forward to assisting them to scale quickly and improve their workflow through the type of innovation that elevates our solutions above those offered by our competitors.”

“At Surpass, we believe the key to our growth is providing world class service to our clients while maximizing operating efficiencies. We are excited to bring Sphere 3D’s hybrid cloud solutions into our newest 80-seat call center located in Lynchburg, VA. Additionally, we plan on leveraging their portfolio of services to modernize our current facility without replacing any of our existing hardware,” said Ken Mnemcovich, President at Surpass, LLC. “Sphere 3D’s portfolio supports the flexibility to purchase in a bundled price or a la carte depending on our real time requirements. We anticipate our callers’ average call time (ACT) will shorten and deliver optimal results for our clients. We now have the tools we need to support our virtual desktops while providing secure access to our client data both onsite and in the Microsoft Azure cloud.”

Surpass will deploy a complete hybrid cloud solution that includes Sphere 3D’s V3™ virtual desktop appliances, integrated with software from VMware and managed by Sphere 3D’s Desktop Cloud Orchestrator™ (DCO); 80 seats of Glassware 2.0™ containers for applications virtualization; SnapServer® physical storage for shared storage; and the SnapCLOUD™ virtual storage service in Microsoft Azure.

Surpass will be able to take advantage of a comprehensive cloud solution that offers simple deployment and management while maintaining the ability to scale out as needed. Although this approach provides a complete hybrid cloud experience, it’s delivered at a low total cost of ownership; with the initial call center deployment costing just over $150,000 U.S.

About Sphere 3D

Sphere 3D Corp. (NASDAQ: ANY) delivers containerization and virtualization technologies along with data management products that enable workload-optimized solutions. We achieve this through a combination of containerized applications, virtual desktops, virtual storage and physical hyper-converged platforms. Sphere 3D’s value proposition is simple and direct—we allow organizations to deploy a combination of public, private or hybrid cloud strategies while backing them up with state of the art storage solutions. Sphere 3D, along with its wholly-owned subsidiaries Overland Storage and Tandberg Data, has a strong portfolio of brands including Glassware 2.0™, SnapCLOUD™, SnapScale®, SnapServer®, V3, RDX®, and NEO®. For more information, visit www.sphere3d.com.

# # #

Media Contacts:
Eileen Elam
Sphere 3D
408-283-4734
media.relations@sphere3d.com

Anna Johnston
BWW Communications
+44-1491-636393
anna.johnston@bwwcomms.com

Investor Relations Contact:
Mike Bishop
The Blueshirt Group
+1 415-217-4968
mike@blueshirtgroup.com

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, unforeseen changes in the course of Sphere 3D’s business or the business of its wholly-owned subsidiaries, including, without limitation, Overland Storage and Tandberg Data; any failure in the functionality or performance of our products; the level of success of our collaborations and business partnerships; possible actions by customers, partners, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in Sphere 3D’s periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov). Sphere 3D undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

(NXTD)New DreamTrips Smart Card Developed by NXT-ID to Over 22,000 Members

MELBOURNE, Florida, January 19, 2016 /PRNewswire/ —

NXT-ID, Inc. (NASDAQ:NXTD) (“NXT-ID” or the “Company”), a company focused on the growing mobile commerce market, reports the new smart card being developed for WorldVentures Vacation Club Members was introduced to an enthusiastic audience at their annual UNITED conference, held in Orlando, Fla. Jan. 15-17^th .

On Jan. 4, WorldVentures and NXT-ID, Inc. announced a strategic alliance to develop a proprietary new wireless smart card for its Members, based on NXT-ID’s Wocket® smart wallet technology.

According to WorldVentures, “Over 22,000 Independent Representatives came together to celebrate past successes, look ahead to the next decade with innovative new technologies and travel products, and give back to the Orlando community.”

During the conference, WorldVentures introduced the DreamTrips smart card, being developed exclusively for them by NXT-ID, that will be customized with additional technologies and wireless features, such as the ability to seamlessly integrate with the WorldVentures DreamTrips App to wirelessly check in and earn loyalty points towards free DreamTrips vacations at select restaurants.

WorldVentures currently has approximately 500,000 DreamTrips Members, with as many as 80,000 new Members joining every month. The vision of WorldVentures’ executive team is to make the smart card available to every existing Member, and provide a Member kit to every new Member that includes the smart card purchased from NXT-ID.

In the presentation to Members, it was demonstrated how the new smart card, just like the Wocket card designed to replace all the cards in your wallet, the new DreamTrips card will make travel and vacationing simpler and more secure.

David Tunnell, Executive Vice-President and Chief Technology Officer for NXT-ID was invited onstage during the smart card presentation. He said, “We received an overwhelmingly enthusiastic and positive reception at the convention. It was quite an experience being in front of tens of thousands of people and witness the support for our smartcard technology.”

Video:  WorldVentures conference clip: https://youtu.be/I1Q99GMktr4

About WorldVentures

WorldVentures Marketing, LLC is the leading international direct seller of vacation club memberships and helps people achieve more fun, freedom and fulfillment by offering DreamTrips™ memberships, which include premium vacations at reduced prices. WorldVentures is a privately held company based in Plano, Texas, with active Representatives and Members in 28 countries. For more information, please visit http://www.worldventures.com.

About NXT- ID Inc. – Mobile Security for a Mobile World

NXT-ID, Inc.’s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of solutions that secure consumers’ mobile platforms led by Wocket®; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. http://www.wocketwallet.com/

NXT-ID’s wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Product images are available for media at: http://press.nxt-id.com

Wocket® is the smartest wallet you’ll ever own. Designed to protect your identity and replace your old wallet, simply save your cards into Wocket once and they are immediately secured. You can choose a card from the touch screen and Wocket programs its single, smart card (Wocket Card) or uses its NFC touch to pay technology to match your selection. Your Wocket can be used virtually anywhere that credit cards are accepted today. Wocket can also display a variety of barcodes.

All your credit, debit, loyalty, gift, ID, membership, insurance, medical information, passwords, and virtually any other information can be protected on Wocket®.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:
Corporate info: info@nxt-id.com

Media:
D. Van Zant
1-800-665-0411
press@nxt-id.com

(ACOR) to Acquire (BITI)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) for €23.5680 per ADS in cash, or the equivalent of $25.60 per ADS based on an exchange rate of 1.0864 U.S. dollars to euros, which values Biotie at approximately $363 million.

Acorda will obtain worldwide rights to tozadenant, an oral adenosine A_2a receptor antagonist currently in Phase 3 development in Parkinson’s disease (PD). In a Phase 2b clinical trial, tozadenant reduced average daily OFF time as an adjunct to treatment regimens including levodopa/carbidopa.

Further expanding its Parkinson’s pipeline, Acorda will also obtain global rights to SYN120, an oral, 5-HT₆/5-HT_2A dual receptor antagonist for Parkinson’s-related dementia, in Phase 2 development with support from the Michael J. Fox Foundation.

“Our acquisition of Biotie positions Acorda as a leader in Parkinson’s disease therapeutic development, with three clinical-stage compounds that have the potential to improve the lives of people with Parkinson’s. Tozadenant, Biotie’s most advanced clinical program, is a promising therapy being developed to reduce daily OFF time,” said Ron Cohen, M.D., Acorda’s President and CEO. “Adenosine A_2a receptor antagonists may be the first new class of drug approved for the treatment of Parkinson’s in the U.S. in over 20 years. Approximately 350,000 people with Parkinson’s in the U.S. experience OFF periods, and if approved, tozadenant could provide a much needed treatment option.”

Dr. Cohen added, “Tozadenant is a compelling opportunity with potential market exclusivity to 2030. The Phase 2 data were highly statistically significant and clinically meaningful. We are targeting an NDA filing by the end of 2018.”

Tozadenant is an orally administered, potent and selective antagonist of the adenosine A_2A receptor. Adenosine is a neurotransmitter, one of the naturally occurring chemical messengers that transmit signals between neurons in the brain. The A_2a receptor is one of the types of chemical receptors on neurons that mediate the adenosine signal. This receptor is expressed particularly in the motor control part of the brain that is affected in people with Parkinson’s. Activation of the A_2a receptor has effects in the brain that antagonize the action of another neurotransmitter, dopamine, in this brain region. A loss of dopamine input is a central mechanism of PD and treatment with levodopa is designed to restore more normal dopamine levels in the brain. Blocking of A_2a receptors with tozadenant serves to dampen the antagonistic effect of adenosine on dopamine and thereby promotes motor function.

A 420-patient Phase 2b trial published in Lancet Neurology compared four different doses of tozadenant to placebo, using patient diaries to record OFF time in patients on a stabilized regimen of levodopa and up to three additional medications. OFF time is characterized by a re-emergence of PD motor symptoms, such as impaired ability to move, muscle stiffness and tremor. The average daily OFF time for individuals receiving tozadenant at the 120 mg dose decreased by 1.9 hours, or 1.1 hours relative to placebo (5.9 hours per day at baseline to 4.0 hours at twelve weeks). Notably, this improvement in OFF time was not associated with significant increases in troublesome dyskinesia for doses being studied in the ongoing Phase 3 program (60mg and 120 mg).

The most common adverse events in the this trial for the 60 mg and 120 mg dose groups were: dyskinesia (14% in the 60 mg group, 16% in the 120 mg twice-daily group, 8% placebo group); nausea (6% in the 60 mg group, 9% in the 120 mg twice-daily group, 4% placebo group); and dizziness (5% in the 60 mg group, 5% in the 120 mg twice-daily group, 1% placebo group). Serious adverse events were reported in 13 patients (placebo – 3; tozadenant: 60 mg – 1, 120 mg – 3, 180 mg – 2, 240 mg – 4). There were six deaths in this study (placebo – 0; tozadenant: 60 mg -1, 120 mg – 0, 180 mg – 2, 240 mg – 3). Neither the drug safety monitoring board (DSMB) nor a second panel of experts who reviewed the data identified a relationship between treatment with tozadenant and serious adverse events or deaths.

Biotie is headquartered in Turku, Finland, with clinical operations based in South San Francisco, CA. Following the close of the acquisition, Acorda plans to maintain the South San Francisco location and retain Biotie staff at that site. Acorda is considering the long-term future of the Turku facility. With this addition, Acorda will have operations in three major U.S. biotechnology centers: New York, Boston and San Francisco.

Mr. William M. Burns, Chairman of the Board of Biotie, commented, “We have carefully assessed the terms and conditions of the offer and believe that it is an attractive offer to shareholders that recognizes the strategic value of Biotie.”

Mr. Burns continued, “With the shared mission to improve the lives of patients with neurological diseases, this transaction will allow Acorda and Biotie to bring together their expertise and resources in order to fully maximize the potential of tozadenant, an A_2a receptor antagonist in Phase 3 for Parkinson’s disease, and SYN120 a dual 5-HT₆/5-HT_2A receptor antagonist in Phase 2 for cognitive and psychotic disorders, and to bring new medicines to patients. We are excited about this offer for our shareholders, the Biotie team and for patients.”

The acquisition also includes two other assets: BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC), a chronic liver disease; and double-digit royalties from sales of Selincro^®, a European Medicines Agency (EMA)-approved therapy for reduction in alcohol consumption marketed by H. Lundbeck A/S in multiple European countries.

The $363 million all-cash tender offer in Finland and the United States is unanimously recommended by Biotie’s Board of Directors. The transaction was also unanimously approved by Acorda’s Board of Directors. Subject to customary closing conditions, the tender offer is expected to be completed in the first or second quarter of 2016, and the acquisition is expected to be completed in the third quarter of 2016.

Financing Transactions

Concurrently with the announcement of the Biotie transaction, Acorda announced two separate financing transactions.

Acorda has agreed to issue $75 million of common stock (the “Shares”) in a private placement transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). Acorda intends to use the net proceeds from the issuance of the Shares to fund, in part, the acquisition of Biotie described above. The issuance of the Shares is not contingent upon the consummation of the acquisition of Biotie or the terms of the acquisition. If the acquisition of Biotie is not consummated for any reason, the Company will use all of the net proceeds from the issuance of the Shares for general corporate purposes. The closing of the private placement is expected to occur in January 2016 and is subject to customary closing conditions.

Acorda also received a commitment from JPMorgan Chase, N.A. for an asset-based loan facility for up to $60 million. The closing of this transaction is expected to occur within six weeks and is subject to customary closing conditions.

The Shares will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements or a transaction not subject to the registration requirements of the Securities Act or any state securities laws.

This press release is issued pursuant to Rule 135(c) under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.

Acorda had $353 million in cash at year-end 2015 (unaudited). Following the close of the transaction, the Company expects the net proceeds from the common stock issuance, together with the availability under the asset-based credit facility, to be sufficient to fund ongoing operations.

Lazard, MTS Health Partners and J.P. Morgan Securities LLC served as financial advisors, and Kirkland & Ellis, Roschier, Covington & Burling LLP and Jones Day LLP served as legal advisors to Acorda in connection with this transaction. Guggenheim Securities served as Biotie Therapies’ financial advisors, and Davis Polk & Wardwell LLP and Hannes Snellman Attorneys Ltd. served as Biotie’s legal advisors.

Webcast and Conference Call

Ron Cohen, President and Chief Executive Officer, and Michael Rogers, Chief Financial Officer, will host a conference call today at 8:00 a.m. ET.

To participate in the conference call, please dial 855-542-4209 (domestic) or 412-455-6054 (international) and reference the access code 31734527. The presentation will be available via a live webcast on the Investor section of www.acorda.com.

A replay of the call will be available from 11:00 a.m. ET on January 19, 2016 until midnight on January 26, 2016. To access the replay, please dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference the access code 31734527. The archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at www.acorda.com.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including multiple sclerosis, Parkinson’s disease, post-stroke walking deficits, epilepsy and migraine. Acorda markets three FDA-approved therapies, including AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg.

About Biotie Therapies

Biotie Therapies is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Its pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease. In addition, Biotie has successfully developed a product for alcohol dependence that is being commercialized by Lundbeck and is a source of further potential milestone payments and ongoing royalties.

Forward-Looking Statement

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to complete the Biotie transaction on a timely basis or at all; the ability to realize the benefits anticipated to be realized by the Biotie transaction and the Civitas transaction; the ability to successfully integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies. In addition, the compounds being acquired from Biotie are subject to all the risks inherent in the drug development process, and there can be no assurance that these compounds will receive regulatory approval or be commercially successful. These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Additional Information

The tender offer described in this release has not yet commenced, and this release is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, we will file, or will cause a new wholly owned subsidiary to file, with the SEC a tender offer statement on Schedule TO. Investors and holders of Biotie Equity Interests are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by Biotie with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov upon the commencement of the tender offer. In addition, a copy of the offer to purchase, letter of transmittal and other related tender offer documents (once they become available) may be obtained free of charge by directing a request to us at www.acorda.com or Office of the Corporate Secretary, 420 Saw Mill River Road, Ardsley, New York 10502.

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, we file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by us at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. our filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

THE OFFER WILL NOT BE MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE EITHER AN OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHERE ANY TENDER OFFER DOCUMENT OR REGISTRATION OR OTHER REQUIREMENTS WOULD APPLY IN ADDITION TO THOSE UNDERTAKEN IN FINLAND AND THE UNITED STATES.

IN ADDITION, THE TENDER OFFER DOCUMENTS, THIS RELEASE AND RELATED MATERIALS AND ACCEPTANCE FORMS WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW. IN PARTICULAR, THE TENDER OFFER IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG. THE TENDER OFFER CANNOT BE ACCEPTED BY ANY SUCH USE, MEANS OR INSTRUMENTALITY OR FROM WITHIN CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG.

Acorda Therapeutics
Investors
Felicia Vonella, 914-326-5146
fvonella@acorda.com
or
Media
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com

(CNCK) Issues Letter to Shareholders on Status of Company, Future Uplisting

(AMRS) Launches Pathways Program

Provides Partners With Low-Cost, Low-Risk Opportunity to Access Transformational Technology Platform

EMERYVILLE, Calif., Jan. 15, 2016  — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the availability of its Pathways Program, a program that provides partners a low-cost, low-risk opportunity to access Amyris’s industry-leading synthetic biology technology. Through the Pathways Program, partners can, with a small initial investment, sponsor and secure a molecule they are interested in having Amyris produce using the next-generation tools and technologies being developed through the company’s recently announced technology investment agreement with the Defense Advanced Research Projects Agency (DARPA). Amyris expects the powerful combination of its existing core technology and bioengineering advancements enabled by its project with DARPA will significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology. The Pathways Program allows partners to access these latest developments and explore bio-synthetic production opportunities with minimal risk and commitment.

Provides Partners a De-Risked Opportunity to Explore Development of New Molecules with a Leader in Synthetic Biology

The Pathways Program provides partners with a de-risked opportunity to use Amyris’s expert capabilities and advanced tools and methodologies for the construction of organisms that convert sugar to the partner’s target molecule. The successful completion of the organism engineering potentially provides a new mode of production with secure stable supply from a renewable resource.

In essence, this program opens up Amyris’s advanced technology platform and leading capabilities to researchers and companies wishing to determine the viability of biological production of target molecules at a lower cost and with minimized risk.

“Our Pathways Program provides partners with a unique and advantaged opportunity to access cutting-edge technologies that are at the forefront of bioengineering to explore the development of new materials with little upfront risk,” said John Melo, President & CEO at Amryis. “Our mission is to accelerate the transition to a world that uses sustainably sourced bio-materials and we believe that making our technology more accessible removes a key barrier to making lower cost, higher performing products for a healthier planet. We have now created several $100-million-dollar supply opportunities for our renewable farnesene technology and expect many more building blocks, like farnesene, to come from opening our platform to the world.”

For partners interested in accessing faster, lower cost to market for sustainable biochemistry please contact Cindy Bryant, Amyris’s Senior Vice President Corporate Development & Collaborations at 510-450-0761 ext. 468.

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as Amyris’s ability to offer molecule development services at low risk and low cost to potential partners and the ability of Amyris technology, existing and under development, to significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 9, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris and the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.

Contacts:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com

(TSEM) to Take Part in the Drexel Management Call Series, January 19, 2016

MIGDAL HAEMEK, Israel, Jan. 15, 2016  — TowerJazz (NASDAQ: TSEM), the global specialty foundry leader, today announced that its Chief Executive Officer, Russell Ellwanger, CFO, Oren Shirazi and Head of Investor and Public Relations, Noit Levi, will be attending and taking part in the Drexel Hamilton quarterly management call series. In addition to the Drexel analyst’s questions, there will be an opportunity for investors to ask management questions directly.

The call will take place at 10:00 am EST on Tuesday, January 19.

To participate please dial: 1 719 325 2630; with conference key 401593.

About TowerJazz

Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM), its fully owned U.S. subsidiary Jazz Semiconductor, Inc. and its fully owned Japanese subsidiary TowerJazz Japan, Ltd., operate collectively under the brand name TowerJazz, the global specialty foundry leader. TowerJazz manufactures integrated circuits, offering a broad range of customizable process technologies including: SiGe, BiCMOS, Mixed-Signal/CMOS, RF CMOS, CMOS Image Sensor, integrated Power Management (BCD & 700V), and MEMS capabilities. TowerJazz also provides a world-class design enablement platform for a quick and accurate design cycle as well as Transfer Optimization and development Process Services (TOPS) to IDMs and fabless companies that need to expand capacity.

To provide multi-fab sourcing and extended capacity for its customers, TowerJazz operates two manufacturing facilities in Israel (150mm & 200mm), one in the U.S. (200mm), and four in Japan (200mm & 300mm). Three of the Japan fabs are available through TowerJazz Panasonic Semiconductor Company (TPSCo), established with Panasonic Corporation of which TowerJazz has the majority holding. Through TPSCo, TowerJazz offers leading edge 45nm CMOS, 65nm RF CMOS and 65nm 1.12um pixel technologies. For more information, please visit: www.towerjazz.com.

CONTACT: Tower Semiconductor
         Noit Levi, +972 4 604 7066
         Noit.levi@towerjazz.com

         GK Investor Relations
         Kenny Green, (646) 201 9246
         towerjazz@gkir.com

(FORK) to Supply Leading U.S. Distributor Bunzl’s Western Region

ALLENTOWN, Pa., and TAIZHOU, China, Jan. 15, 2016  — Fuling Global Inc. (NASDAQ: FORK) (“Fuling Global” or the “Company”), a specialized producer and distributor of environmentally-friendly plastic serviceware, with precision manufacturing facilities in both the U.S. and China, today announced that its U.S. subsidiary Domo Industry Inc. (“Domo”) has agreed to supply disposable cutlery to the western region of Bunzl Distribution USA Inc. (“Bunzl USA”). Bunzl USA is a leading supplier of a wide range of products serving the food industry, including outsourced food packaging, disposable supplies, and cleaning and safety products to food processors, supermarkets, non-food retailers, convenience stores and other users. Bunzl USA is the largest subsidiary of Bunzl plc, an international distribution and outsourcing group listed on the London Stock Exchange.

Starting from this month, Domo will begin supplying disposable plastic serviceware, including cutlery, polyethylene terephthalate (“PET”) cups, and calcium polypropylene (“PP”) hinged containers, to the western region of Bunzl USA’s R3 Redistribution Division (“R3”). Headquartered in Chicago, IL, R3 services the U.S., Canada, Mexico and Puerto Rico markets with over 74 shipping facilities, 2,600 professionals and one of largest trucking fleets in North America, which features more than 450 tractors and 650 trailers.

Mr. Lee Yu, Vice President of Domo, commented, “We have been discussing cooperation with Bunzl USA for some time. Our reputation as a quality supplier in the U.S. market, the launch of our Allentown manufacturing facility and Fuling’s recent NASDAQ listing helped us reach this significant relationship with Bunzl USA. Domo will begin supplying disposable cutlery to R3’s Los Angeles and Seattle branches immediately, with PET cups and calcium PP hinged containers to follow. We also hope to supply straws produced at Fuling Global’s Allentown, PA facility and other products to R3 in the future.”

“We are excited about the opportunities this new cooperation with Bunzl USA provides Fuling,” said Mr. Xinfu Hu, Chief Executive Officer of Fuling Global. “With its extensive network of warehouses, distribution centers and sizable trucking fleet, Bunzl USA gives us an excellent platform to further penetrate the U.S. market. Kudos to the Domo Team and we look forward to continuing to grow this relationship for years to come.”

About Bunzl Distribution USA, Inc.

Bunzl Distribution USA, Inc. (“Bunzl USA”) supplies a range of products including outsourced food packaging, disposable supplies, and cleaning and safety products to food processors, supermarkets, non-food retailers, convenience stores and other users. Based in St. Louis, Missouri, Bunzl USA is the largest division of Bunzl plc, an international distribution and outsourcing group listed on the London Stock Exchange. Bunzl USA owns and operates more than 100 warehouses that serve all 50 states and Puerto Rico, as well as Canada, the Caribbean and parts of Mexico. With more than 4,000 employees and 400,000-plus supply items, Bunzl USA is regarded as one of the leading suppliers in North America.

About Fuling Global Inc.

Fuling Global Inc. (“Fuling Global”) is a specialized producer and distributor of environmentally friendly plastic serviceware, with precision manufacturing facilities in both the U.S. and China. The Company’s plastic serviceware products include disposable cutlery, drinking straws, cups, plates and other plastic products and are used by more than one hundred customers primarily from the U.S. and Europe, including Subway, Wendy’s, Burger King, KFC (China only), Walmart, McKesson, and Woolworths. More information about the Company can be found at: http://ir.fulingglobal.com/.

Forward-Looking Statements

This press release contains information about Fuling Global’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of software and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Fuling Global encourages you to review other factors that may affect its future results in Fuling Global’s registration statement and in its other filings with the Securities and Exchange Commission.

For more information, please contact:

At the Company:
Gilbert Lee, CFO
Email: ir@fulingplasticusa.com
Phone: +1-610-366-8070×1835
Web: http://ir.fulingglobal.com/

Investor Relations:
Tina Xiao
Weitian Group LLC
Email: fork@weitian-ir.com
Phone: +1-917-609-0333

(DGLY) USPTO Confirms Validity of Revolutionary ‘292 Patent on Body Camera Tech

Digital Ally Files Lawsuit Against TASER International, Inc. for Willful Infringement and Seeks an Injunction Preventing TASER From Selling Its Axon Body Camera Product Line

(NVLS) Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis

Designation Marks Important Milestone in the Development and Regulatory Pathway for the First CFTR Stabilizer

BOULDER, Colo., Jan. 15, 2016  — Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (“CF”), today announced the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to the Company’s lead investigational drug, N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

“The Orphan Drug Designation represents an important milestone in the development and regulatory strategy for N91115 and underscores the unmet need that remains in treating CF,” said Jon Congleton, president and chief executive officer of Nivalis. “We look forward to the continued clinical advancement of this first-in-class CFTR stabilizer, a new approach to modulating the defective CFTR protein.”

The Company recently initiated a Phase 2, 12-week, double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy and safety of N91115 in 135 adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with Orkambi™. Results of this study are planned to be reported in the second half of 2016. N91115 works through a novel mechanism of action called S-nitrosoglutathione reductase (GSNOR) inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF.

The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.

The Company will also seek Fast Track status for its development program with N91115. A Fast Track designation enables more frequent interactions with the FDA to expedite the development and review process for drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

For more information on the Phase 2 study, please visit ClinicalTrials.gov and reference Identifier NCT02589236.

About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with cystic fibrosis (CF). In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

About N91115
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominately in the United States and Europe, according to the Cystic Fibrosis Foundation (www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene. N91115 works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect increases and prolongs the function of the CFTR chloride channel and leads to an increase in net chloride secretion. Nivalis discovered and owns exclusive rights to N91115 in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031.

Nivalis Therapeutics has completed clinical studies with N91115, including a Phase 1a dose-escalation safety study in healthy volunteers, and a Phase 1b safety study in people with CF who have two copies of the F508del mutation. In preclinical studies, N91115 has been shown to increase the function of F508del-CFTR, the mutant protein that is estimated to be present in approximately 86 percent of people with CF in the United States and Europe.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the risk that the timing of site initiation and patient enrollment for our clinical trials may take longer than expected, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s prospectus filed with the Securities and Exchange Commission on June 17, 2015, in the company’s most recent quarterly report on Form 10-Q and in its other reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law. 

Contacts:

Investor Relations 
John Graziano
1-646-378-2942
jgraziano@troutgroup.com

Media Relations 
Lindsay Rocco
1-862-596-1304
lrocco@elixirhealthpr.com

(SYUT) Announces Receipt of Preliminary Non-Binding “Going Private” Proposal

QINGDAO, China and ROCKVILLE, Md., Jan. 15, 2016  — Synutra International, Inc. (Nasdaq: SYUT), (“Synutra” or the “Company”), which owns subsidiaries in China that produce, distribute and sell nutritional products for infants, children and adults, today announced that its board of directors (the “Board”) has received a non-binding proposal letter, dated January 14, 2016, from Mr. Liang Zhang (“Mr. Zhang”), Chairman and chief executive officer of Synutra, and an affiliated entity of his (together with Mr. Zhang, the “Buyer Group”), proposing a “going-private” transaction (the “Transaction”) to acquire all of the outstanding common stock (the “Shares”) of the Company not already owned by the Buyer Group for US$5.91 in cash per Share, subject to certain conditions, which represents a premium of approximately 63% to the closing price of the Company’s Shares on January 13, 2016, and a premium of approximately 30% to the volume-weighted average closing price of the Company’s Shares during the last 20 trading days.

According to the proposal letter, the Buyer Group intends to fund the consideration payable in the Transaction with a combination of equity capital and third party debt, and rollover equity in the Company. A copy of the proposal letter is attached as Annex A to this press release.

The Board intends to form a special committee consisting of independent directors to consider this proposal.

The Board cautions the Company’s shareholders and others considering trading in its securities that the Board just received the non-binding proposal letter from the Buyer Group and no decisions have been made with respect to the Company’s response to the Transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products through its operating subsidiaries under the “Shengyuan” or “Synutra” name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering all provinces and provincial-level municipalities in mainland China. As of September 30, 2015, this network comprised over 770 independent distributors and over 290 independent sub-distributors who sell Synutra products in approximately 22,800 retail outlets.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations, assumptions, estimates and projections about Synutra and its industry. All statements other than statements of historical fact in this release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “is/are likely to,” “may,” “plan,” “should,” “will,” “aim,” “potential,” “continue,” or other similar expressions. The forward-looking statements included in this press release relate to, among others, Synutra’s goals and strategies; its future business development, financial condition and results of operations, particularly the progress on the new drying facility project in France; the expected growth of the nutritional products and infant formula markets in China; market acceptance of Synutra’s products; the safety and quality of Synutra’s products; Synutra’s expectations regarding demand for its products; Synutra’s ability to stay abreast of market trends and technological advances; competition in the infant formula industry in China; PRC governmental policies and regulations relating to the nutritional products and infant formula industries and our ability to meet governmental requirements, and general economic and business conditions in China. These forward-looking statements involve various risks and uncertainties. Although Synutra believes that the expectations expressed in these forward-looking statements are reasonable, these expectations may turn out to be incorrect. Synutra’s actual results could be materially different from the expectations. Important risks and factors that could cause actual results to be materially different from expectations are generally set forth in Synutra’s filings with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this press release. Synutra undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Annex A

January 14, 2016

The Board of Directors
Synutra International, Inc.
2275 Research Blvd., Suite 500
Rockville, Maryland 20850
United States

Dear Members of the Board of Directors,

Mr. Liang Zhang (“Mr. Zhang“), chairman of the board of directors of Synutra International, Inc. (the “Company“), and Beams Power Investment Limited (together with Mr. Zhang, the “Buyer Parties“), an investment vehicle wholly owned by Mr. Zhang’s wife, Ms. Xiuqing Meng, are pleased to submit this preliminary non-binding proposal to acquire all of the outstanding shares of common stock (the “Shares“) of the Company that are not already beneficially owned by the Buyer Parties in a going private transaction (the “Transaction“).

We believe that our proposal of US$5.91 per Share in cash provides a very attractive opportunity to the stockholders of the Company. This price represents a premium of approximately 63% to the closing price of the Company’s Shares on January 13, 2016 and a premium of approximately 30% to the volume-weighted average closing price of the Company’s Shares during the last 20 trading days.

The terms and conditions upon which we are prepared to pursue the Transaction are set forth below.  We are confident in our ability to consummate the Transaction as outlined in this letter.

1.      Transaction and Purchase Price

We propose to acquire all of the outstanding Shares of the Company not beneficially owned by us at a purchase price equal to US$5.91 per Share in cash through a merger of an acquisition vehicle newly formed by the Buyer Parties with and into the Company.

2.      Financing 

We intend to finance the Transaction with a combination of equity capital and third party debt. Equity financing will be provided by the Buyer Parties, and any additional equity investor who may be admitted as a Buyer Party, in the form of cash and rollover equity in the Company. Debt Financing is expected to be provided by loans from third party financial institutions. We are confident that we can timely secure adequate financing to consummate the Transaction.

3.      Due Diligence 

We believe that we will be in a position to complete customary business, legal and financial due diligence for the Transaction in a timely manner and in parallel with discussions on definitive agreements.

4.      Definitive Agreements 

We have engaged Davis Polk & Wardwell LLP as our U.S. legal counsel.  We are prepared to negotiate and finalize definitive agreements for the Transaction promptly.  These documents will include provisions typical for transactions of this type.

5.      Confidentiality 

The Buyer Parties will, as required by law, promptly file an amendment to Schedule 13D with the Securities and Exchange Commission to disclose this letter.  We are sure you will agree that it is in all of our interests to ensure that we otherwise proceed in a strictly confidential manner, unless otherwise required by law, until we have executed definitive agreements or terminated our discussions.

6.      Process

We believe that the Transaction will provide value to the Company’s stockholders. We recognize of course that the board of directors of the Company will evaluate the proposed Transaction independently before it can make its determination whether to endorse it. In considering the Transaction, you should be aware that we are interested only in acquiring the outstanding Shares that the Buyer Parties do not already own, and that the Buyer Parties do not intend to sell their stake in the Company to a third party.

7.      No Binding Commitment 

This proposal is not a binding offer, agreement or agreement to make a binding offer or agreement at any point in the future. This letter is a preliminary indication of interest by the Buyer Parties and does not contain all matters upon which agreement must be reached in order to consummate the Transaction, nor does it create any binding rights or obligations in favor of any person. The parties will be bound only upon the execution of mutually agreeable definitive documentation.

* * * * * *

In closing, we would like to express our commitment to working together to bring this Transaction to a successful and timely conclusion. Should you have any questions regarding this proposal, please do not hesitate to contact us. We look forward to hearing from you.

Yours sincerely,

Liang Zhang
/s/ Liang Zhang

Beams Power Investment Limited

By: /s/ Xiuqing Meng
Name: Xiuqing Meng
Title: Director

(LPTH) Exhibiting at SPIE Photonics West 2016

LightPath to Show New Products to an Expected 20,000 Attendees and 1,250 Vendors

(TUES) Announces Reporting Date for Q2 Fiscal 2016 Financial Results

DALLAS, Jan. 14, 2016  — Tuesday Morning Corporation (NASDAQ:TUES) today announced that the Company will hold a conference call to discuss its second quarter fiscal 2016 financial results on Friday, January 29^th, 2016 at 8:00 am Central Time. A press release detailing the Company’s financial results will be issued before the market opens and prior to the conference call.

A live webcast of the conference call will be available in the investor relations section of the Company’s website, www.tuesdaymorning.com. Investors and analysts interested in participating in the call are invited to dial (877) 312-5376 approximately ten minutes prior to the start of the call. A replay of the webcast will be posted on the website for 90 days. A replay of the conference call will also be available from 11:00 am Central Time Friday, 1/29/2016 through 10:59 pm Central Time, Sunday, 1/31/2016 by dialing (855) 859-2056 or (404) 537-3406 and entering conference ID number 28918021.

About Tuesday Morning

Tuesday Morning Corporation (NASDAQ:TUES) is a leading off-price retailer specializing in selling deeply discounted, upscale decorative home accessories, housewares, seasonal goods and famous-maker gifts.  The Company is nationally known for providing a fresh selection of brand name, high-quality merchandise – never seconds or irregulars – at prices well below those of department and specialty stores, catalogues and online retailers.  Based in Dallas, Texas, the Company opened its first store in 1974 and currently operates over 750 stores in 41 states.  More information and a list of store locations may be found on our website at www.tuesdaymorning.com.

CONTACT: Farah Soi/Caitlin Morahan
ICR                                    
203-682-8200
Farah.Soi@icrinc.com
Caitlin.Morahan@icrinc.com

MEDIA: Jonathan Morgan/Jennifer Sanders
PERRY STREET COMMUNICATIONS
214-965-9955